Predict your next investment

Rentschler Biopharma company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer

About Rentschler Biopharma

Rentschler Biopharma is a full-service CDMO that supports global clients through to market approval of their products. The company's clients include biotech companies and pharmaceutical companies.

Rentschler Biopharma Headquarter Location

Erwin-Rentschler-Str. 21

Laupheim, 88471,


+49 73927010

Latest Rentschler Biopharma News

Single-Use Bioprocessing Market Size to Surpass US$ 52.5 Bn by 2030

Oct 20, 2021

Companies Mentioned General Electric Company (GE Healthcare), PBS Biotech, Inc., Thermo Fisher Scientific, Inc., Infors AG, Sartorius AG, Merck KGaA, Entegris, Inc., Lonza, Pall Corporation, Corning Incorporated, Eppendorf AG, Rentschler Biopharma SE Regional Snapshots North America is the leading single-use bioprocessing market owing to the increased spending on healthcare, technological development in bioprocessing, and growing importance of life science research. Growing adoption of disposable systems and increased energy efficiency coupled with the minimal risk of product cross-contamination are the beneficial factors associated with the use of single-use bioprocessing products. Further, the introduction of automation, big data technology, and artificial intelligence in the single-use system has been gaining rapid traction in North America. These latest technologies in the manufacturing units are expected to boost production and helps the manufacturers to achieve cost-efficiency and reduce wastages.The presence of a large number of big and small contract manufacturing organizations in the region are increasingly using the single-use bioprocessing technology due to its low cost and improved output. The increased economic activity of these contract manufacturers will significantly drive the growth of the single-use bioprocessing market in North America. Asia Pacific is characterized by growing production of biosimilars, cell therapy, vaccines, and various other types of biopharmaceutical products. Moreover, China is the second largest biopharmaceutical market just after the US. China’s economic policies to attract FDIs for setting up manufacturing plants for biopharmaceutical products is exponentially fostering the demand for single-use bioprocessing technology. Moreover, nations like India, Japan, and South Korea have been a leading player in the Asia Pacific region. Biocon of India and Samsung Biologics of South Korea have earned FDA and European Medicines Agency approval respectively, for their new biosimilar products in 2017. Therefore, the single-use bioprocessing market has huge growth potential in the Asia Pacific region. Report Highlights By product, the media bags and containers segment led the global single-use bioprocessing market with remarkable revenue share in 2020. This is due to the benefits associated with the media bags and containers such as low capital requirement, saving of cost in sterilization and cleaning, operating scale flexibility, quick batch changeover and quick deployment, and cleaning validation elimination. By application, the filtration segment led the global single-use bioprocessing market with remarkable revenue share in 2020. This is attributed to the increasing adoption of single-use bioprocessing system in filtration owing to its flexibility. It is applicable in a wide variety of biopharmaceutical applications depending on the type of solutions used and is very much effective in eliminating viruses and other such cultures. By End User, the biopharmaceutical manufacturer segment led the market in 2020 as rapid growth of biopharmaceuticals industry. Biopharmaceutical industry alone represents over 20% of the total pharmaceutical industry and is rapidly growing across the markets like North America and Europe. Ask Here for Customization Requirement@ Market Dynamics Drivers - The single-use bioprocessing market is significantly driven by the growing demand from the biopharmaceutical industry. Majority of the biopharmaceutical companies are increasingly adopting the single-use bioprocessing technology because the single-use bioprocessing systems increases the efficiency in the process and reduces the costs associated with sterilization, cleaning, and maintenance of steel bioreactors. This drives the higher adoption of disposable bioprocessing systems in the biopharmaceutical industry. Restraints - The Bio-Process System Alliance has published a set of tests to be performed regarding the extractable and leachable contamination. The leachable and extractable are the unwanted products produced by the single-use bioprocessing system. The disposable bioprocessing system are made of plastic and often faces contamination issues. This may hamper the single-use bioprocessing market growth. Opportunities - The emerging markets such as China and India have a high growth potential. The growing investments by the major players, growing geriatric population, and rapidly growing biotechnology in the industry is providing lucrative growth opportunities to the single-use bioprocessing market players. Challenges - The plastic wastes generated by the disposable bioprocessing system is a major challenge faced by the market players due to the growing environmental concerns and government regulation regarding plastic wastes. Recent Developments In December 2020, Thermo Fisher Scientific launched a single-use bioreactor for manufacturing cell culture. In March 2020, GE Healthcare’s Biopharma business was acquired by Danaher Corporation and now Biopharma is renamed as Cytiva. The major players in the single-use bioprocessing market are Sartorius AG, Merck KGaA, Pall Corporation, Rentschler Biopharma SE, Corning Incorporated, Eppendorf AG, Thermo Fisher Scientific, Inc., General Electric Company (GE Healthcare), and Lonza. Market Segmentation Buy this Premium Research Report@ You can place an order or ask any questions, please feel free to contact at  | +1 9197 992 333 About Us Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Rentschler Biopharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Rentschler Biopharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.